FDAnews Device Daily Bulletin

JOHNSON & JOHNSON 'NEUTRAL,' TARGET PRICE REDUCED

Nov. 9, 2005
A A

Analyst Glenn Novarro of Banc of America Securities maintains his "neutral" rating on Johnson & Johnson. The target price has been reduced from $72 to $65.
Newratings